ZY Mar 2023 2.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 08:30AM EST. Market open.
Loading interactive chart…
- PR Newswire
Ginkgo Bioworks Completes Acquisition of Zymergen
Today, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and Zymergen (Nasdaq: ZY) announced that Ginkgo has completed its previously announced acquisition of Zymergen. The acquisition is expected to significantly enhance Ginkgo's platform by integrating strong automation and software capabilities as well as a wealth of experience across diverse biological engineering approaches.
- Motley Fool
Why Biotech Disruptor Ginkgo Bioworks Is Well-Positioned for the Future
Beaten down from its highs late last year, cell engineering company Ginkgo Bioworks now looks primed to divide and conquer.
© 2023 Yahoo. All rights reserved.
